Weight Loss Injections in India 2026: Mounjaro vs Wegovy vs Ozempic vs Generics
Four routes, prices spanning an order of magnitude, and a genuinely difficult choice. Every option compared on mechanism, trial results, real cost and who each one actually suits.
Five years ago there was essentially one conversation to have about weight-loss medication in India, and for most people the answer was that it was unaffordable. Today there are four viable routes, prices that span an order of magnitude, and a genuinely difficult decision to make.
This guide compares every weight-loss injection currently available in India — Mounjaro, Wegovy, Ozempic and generic semaglutide — on the things that actually decide the outcome: what they do, what they cost, who they suit, and what happens after you stop.
Before you read on
All of these are Schedule H prescription-only medicines. This page is general information to help you have a better-informed conversation with a clinician — not a recommendation, an endorsement, or an offer to supply. Nothing here replaces an assessment, and we do not dispense medication online.
The 2026 Landscape
Two events reshaped this market. Mounjaro launched in India in March 2025 and by October that year had become the country's top-selling drug by value. Then, on 20 March 2026, the Indian patent on semaglutide expired, and dozens of generic manufacturers entered within weeks. Novo Nordisk responded by cutting branded prices twice.
The practical result: the cheapest legitimate route to GLP-1 treatment in India now costs a small fraction of what the most expensive one does. That is a real choice, and it deserves more thought than picking the cheapest line on a price list.
The Four Options, Compared
| Mounjaro | Wegovy | Ozempic | Generic semaglutide | |
|---|---|---|---|---|
| Molecule | Tirzepatide | Semaglutide | Semaglutide | Semaglutide |
| Receptors | GLP-1 + GIP | GLP-1 | GLP-1 | GLP-1 |
| Licensed for | Diabetes and weight | Weight management | Type 2 diabetes | Usually diabetes |
| Form | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| Approx. monthly cost | ₹13,125–25,781 | From about ₹5,660 | Varies by dose | Roughly ₹1,300–4,200 |
| Generic in India | No | n/a | n/a | Yes |
Note the fourth row carefully. It is the row most price comparisons omit, and it is the one most likely to matter to you.
How They Differ Mechanically
Three of the four are the same molecule. The real mechanical divide is between semaglutide and tirzepatide.
- 01Semaglutide — single receptorActs on GLP-1 receptors. Reduces appetite, slows gastric emptying, improves insulin response.
- 02Tirzepatide — dual receptorActs on GLP-1 and additionally GIP receptors. The second pathway is associated with a greater average effect on both appetite and blood sugar.
- 03Everything else is packagingWegovy, Ozempic and generic semaglutide differ in licensed indication, available strengths and device — not in the active molecule.
What the Trials Actually Found
These are published averages from controlled trials with structured support and selected participants. They describe what these medicines can do under good conditions — not what any individual will get.
| Medicine | Trial | Average weight reduction |
|---|---|---|
| Tirzepatide 15 mg | SURMOUNT-1, 72 weeks | About 20.9% |
| Tirzepatide 10 mg | SURMOUNT-1, 72 weeks | About 19.5% |
| Tirzepatide 5 mg | SURMOUNT-1, 72 weeks | About 15.0% |
| Semaglutide 2.4 mg | STEP 1, 68 weeks | About 15% |
| Tirzepatide vs semaglutide | Head-to-head, 72 weeks | About 20.2% vs about 13.7% |
How to read these numbers
Trial participants receive structured dietetic support, regular monitoring and strong adherence prompts. Take the same medicine without those things and the outcome is typically well below the published average. The support is not an optional extra bolted onto the drug — it is part of what produced the number.
Real Costs, Honestly
Sticker price is the beginning of the calculation, not the end.
| Route | Approx. monthly medication cost | Practical notes |
|---|---|---|
| Generic semaglutide | ₹1,300–4,200 | Lowest cost. Check licensed indication and available strengths. |
| Wegovy | From ₹5,660 (0.25 mg) to ₹16,400 (2.4 mg) | Licensed for weight management. Cost rises as you titrate up. |
| Ozempic | Varies by dose | Licensed for diabetes; often the appropriate choice where diabetes is the primary issue. |
| Mounjaro | ₹13,125 (2.5 mg) to ₹25,781 (15 mg) | Highest cost, greatest average effect in trials. Vials can work out cheaper than KwikPens. |
What the medication price does not include
- Initial medical assessment and eligibility screening
- Baseline and follow-up blood tests
- Ongoing consultations while titrating and maintaining
- Dietetic support — the thing that protects muscle as weight falls
- The maintenance phase after you reach your goal
A patient on a low-cost generic with no support frequently spends more over two years than a patient on a mid-priced branded product with proper monitoring — because the first one regains and starts again.
Which Option Suits Whom
There is no universally best choice. There is a best choice for your situation, and these are the factors that usually decide it.
- 01Budget is the primary constraintGeneric semaglutide has made treatment accessible to people for whom it was previously out of reach. Confirm the licensed indication and strengths with your prescriber.
- 02Weight management is the explicit goalWegovy is licensed and dosed specifically for it, which matters for reaching an effective maintenance dose.
- 03Type 2 diabetes is the primary issueOzempic is licensed for exactly this, and the weight effect comes along with it.
- 04Maximum effect and budget allowsTirzepatide showed the greatest average reduction in direct comparison, at the highest cost.
- 05Significant refluxDiscuss this specifically — it influences the choice, and it is frequently overlooked.
Side Effects Across the Class
The side-effect profile is broadly similar across all four, because three share a molecule and the fourth works through an overlapping pathway. Most are gastrointestinal, most noticeable around dose increases, and most settle as your body adjusts.
| Frequency | What you may notice | Management |
|---|---|---|
| Very common | Nausea, constipation, diarrhoea, reflux | Smaller slower meals, avoid greasy and spicy food, hydrate, adjust fibre gradually |
| Common | Fatigue, headache, injection-site reaction | Usually mild; report so the dose can be held rather than pushed through |
| Less common | Gallstones, dehydration, hair thinning | More likely with rapid loss — another reason for a measured pace |
| Rare but serious | Pancreatitis, kidney injury, severe allergic reaction | Stop and seek same-day assessment. Severe abdominal pain radiating to the back needs urgent review. |
Who should not take any of them
- Personal or family history of medullary thyroid carcinoma, or MEN2 syndrome
- Previous pancreatitis, or active gallbladder disease
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
- A current or past eating disorder, without specialist input first
Insulin and sulfonylureas need dose review
If you take either, doses usually need reducing to avoid hypoglycaemia when starting a GLP-1. Bring a complete list of your medications and supplements to your assessment.
What Happens When You Stop
This applies identically to all four options and it is the part price comparisons never mention.
Appetite returns when the medicine wears off, and weight commonly returns with it. This is physiology, not a failure of resolve. It is also entirely plannable — a tapered step-down with protein targets and resistance training established beforehand holds results far better than stopping abruptly.
- Any planned stop is tapered, never abrupt
- Protein and resistance training established before the taper begins
- Review frequency increases during step-down, not after
- Restarting is a legitimate clinical option, discussed openly if regain begins
Key takeaways
- Four routes are now available in India, spanning roughly ₹1,300 to ₹25,781 a month.
- Three of the four are the same molecule — semaglutide — differing in licensed use, strengths and device.
- Tirzepatide showed the greatest average reduction in head-to-head trials, at the highest cost and with no Indian generic.
- Many generics are licensed for diabetes rather than weight management; cheaper is not automatically equivalent.
- Trial averages came from patients receiving structured support — the support is part of what produced them.
- Every option regains weight if stopped without a maintenance plan. Budget for the full course, including the taper.
From our channel
Frequently asked
Which weight loss injection is best in India?
There is no single best. Tirzepatide showed the greatest average reduction in head-to-head trials, generic semaglutide is by far the most affordable, and Wegovy is licensed specifically for weight management. The right one depends on your health picture, comorbidities, tolerance and what you can sustain financially over a full course.
What is the cheapest weight loss injection in India?
Generic semaglutide, reported from roughly ₹1,300 to ₹4,200 per month in 2026 following the March patent expiry. Confirm with your prescriber what indication the specific product is licensed for and which strengths it offers.
Is Mounjaro or Wegovy better for weight loss?
In a direct 72-week comparison, tirzepatide produced about 20.2% average reduction versus about 13.7% for semaglutide. Mounjaro also costs considerably more and has no Indian generic. Greater average effect does not automatically make it the right choice for an individual.
Do weight loss injections work without dieting?
They reduce appetite, which makes eating less far easier — but they do not choose what you eat. Without adequate protein and resistance training, a meaningful share of what you lose is muscle rather than fat, which makes regain more likely.
How quickly do weight loss injections work?
Appetite usually changes within the first few weeks. Weight change is slower and not linear — plateaus are normal and are not a sign the treatment has stopped working.
Are weight loss injections safe long term?
Semaglutide and tirzepatide both have multi-year trial and real-world data and are broadly well tolerated under supervision. Long-term data continues to accumulate. Monitoring exists precisely because this is ongoing medical treatment.
Can I buy weight loss injections online in India?
They are Schedule H prescription medicines and cannot legally be sold without a valid prescription. Falsified GLP-1 pens are a documented international problem. We do not sell or dispense medication online.
Will I need to take it forever?
Not necessarily. Some patients continue long term, others taper successfully with a maintenance plan, and some never need medication at all. It is reviewed at every follow-up rather than decided once.
Do these injections work for PCOS?
GLP-1 medicines are not licensed for PCOS, but weight loss and improved insulin sensitivity often improve PCOS symptoms. Any use in PCOS is a clinical decision made case by case.
What is the difference between a vial and a KwikPen?
A pen is prefilled and fixed-dose; a vial requires drawing the dose yourself. Vials can work out cheaper per dose but demand more careful technique. Most patients default to pens.
Can I switch between these medicines?
Switching is a clinical decision, not a straightforward substitution — doses do not translate directly between tirzepatide and semaglutide. Discuss it at a review rather than changing independently.
What should I budget in total?
Medication is roughly half the picture. Add assessment, bloods, ongoing consultations, dietetic support and the maintenance phase. We set the full figure out in writing before you commit to anything.
Book your consultation
Send your details and we will confirm a time. BMI is worked out for you.